National Institute on Aging (NIA) — Biomedical Watch V2

Traitements6programmes

Essais4liés

Publications12liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Amyloid PET Imaging in the Baltimore Longitudinal Study of AgingBackground: Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or other medical issues. Objective: To learn how amyloids may affect brain structure and function as people age. Eligibility: People aged 55 years and older who are enrolled in the Baltimore Longitudinal Study of Aging. Design: Participants will have imaging scans and other tests every 1 to 4 years, depending on their age. Those 80 and older will be scanned yearly. These scans will be done during regular BLSA visits. The scans will be positron emission tomography and computed tomography (PET CT). Participants will be given fluid through a tube inserted into a vein in their arm. The fluid is a tracer that will cause the amyloids to light up in the images. Then they will lie on a bed with their head inside a PET CT scanner. They will lie still for about 30 minutes. Participants will have tests to assess their memory and other mental skills. They will answer questions about their mood and daily life. These tests will take about 40 minutes to complete; they may be done in person or by phone. Participants will give a contact number for someone who can answer questions about the participant s daily routine. These questions may be answered in person or by phone. Participants will be in this study for 5 years.	Alzheimer	À vérifier	À vérifier	United States	À vérifier
BNCBackground: \- Alzheimer s disease (AD) is a brain disease that impairs memory, cognitive abilities and the ability to function independently. It is the most common cause of dementia in older people. It is caused by abnormal proteins in the brain that affect how neurons communicate with each other. Researchers are looking for drugs that can slow down the disease or treat its symptoms. One drug, called bisnorcymserine (BNC), may help improve brain function and symptoms in people with AD. BNC is designed to block a chemical that affects how neurons communicate with each other. Researchers want to see how BNC works in healthy older volunteers. Objectives: \- To look at how the body processes bisnorcymserine taken by mouth and how safe it is for healthy older volunteers. Eligibility: \- Healthy volunteers at least 55 years of age. Design: * Participants will be screened with a physical exam, medical history, and blood and urine tests. * Within 3 weeks from the screening visit, participants will come to the National Institute on Aging clinical unit for a 2-night stay. On the morning of the second day, they will take either a BNC capsule or a placebo. They will not know which tablet they are taking. * Blood samples will be collected frequently throughout the second and third days of the study visit. The last blood sample will be collected about 32 hours after taking the study capsule. Participants will have heart function tests and other exams during the visit. Once the tests are done, they will leave the clinical center. * Participants will have a final follow-up visit about 1 week after leaving the clinical center.	Alzheimer	Phase 1	Traitement symptomatique	United States	À vérifier
IbuprofenThe purpose of this study is to test the effect of ibuprofen on the levels of a number of different proteins (called biomarkers) in cerebrospinal fluid (CSF), blood, and urine to see whether ibuprofen can influence certain biomarkers associated with the progression of Alzheimer's Disease.	Alzheimer	Phase 1	Ralentissement de la progression	United States	À vérifier
IbuprofenThe purpose of this study is to test the effect of ibuprofen on the levels of a number of different proteins (called biomarkers) in cerebrospinal fluid (CSF), blood, and urine to see whether ibuprofen can influence certain biomarkers associated with the progression of Alzheimer's Disease.	Alzheimer	Phase 1	Ralentissement de la progression + Immunomodulation	United States	À vérifier
Amyloid PET Imaging in the Baltimore Longitudinal Study of AgingBackground: Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or other medical issues. Objective: To learn how amyloids may affect brain structure and function as people age. Eligibility: People aged 55 years and older who are enrolled in the Baltimore Longitudinal Study of Aging. Design: Participants will have imaging scans and other tests every 1 to 4 years, depending on their age. Those 80 and older will be scanned yearly. These scans will be done during regular BLSA visits. The scans will be positron emission tomography and computed tomography (PET CT). Participants will be given fluid through a tube inserted into a vein in their arm. The fluid is a tracer that will cause the amyloids to light up in the images. Then they will lie on a bed with their head inside a PET CT scanner. They will lie still for about 30 minutes. Participants will have tests to assess their memory and other mental skills. They will answer questions about their mood and daily life. These tests will take about 40 minutes to complete; they may be done in person or by phone. Participants will give a contact number for someone who can answer questions about the participant s daily routine. These questions may be answered in person or by phone. Participants will be in this study for 5 years.	Alzheimer	À vérifier	À vérifier	United States	À vérifier
BNCBackground: \- Alzheimer s disease (AD) is a brain disease that impairs memory, cognitive abilities and the ability to function independently. It is the most common cause of dementia in older people. It is caused by abnormal proteins in the brain that affect how neurons communicate with each other. Researchers are looking for drugs that can slow down the disease or treat its symptoms. One drug, called bisnorcymserine (BNC), may help improve brain function and symptoms in people with AD. BNC is designed to block a chemical that affects how neurons communicate with each other. Researchers want to see how BNC works in healthy older volunteers. Objectives: \- To look at how the body processes bisnorcymserine taken by mouth and how safe it is for healthy older volunteers. Eligibility: \- Healthy volunteers at least 55 years of age. Design: * Participants will be screened with a physical exam, medical history, and blood and urine tests. * Within 3 weeks from the screening visit, participants will come to the National Institute on Aging clinical unit for a 2-night stay. On the morning of the second day, they will take either a BNC capsule or a placebo. They will not know which tablet they are taking. * Blood samples will be collected frequently throughout the second and third days of the study visit. The last blood sample will be collected about 32 hours after taking the study capsule. Participants will have heart function tests and other exams during the visit. Once the tests are done, they will leave the clinical center. * Participants will have a final follow-up visit about 1 week after leaving the clinical center.	Alzheimer	Phase 1	Traitement symptomatique	United States	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
BNC	Alzheimer	Phase 1	NCT01747213	Bisnorcymserine in Healthy Adult Volunteers	COMPLETED
Psilocybin	Alzheimer	Phase 2	NCT07721467	Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin	NOT_YET_RECRUITING
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging	Alzheimer	À vérifier	NCT07099053	Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging	RECRUITING
Ibuprofen	Alzheimer	Phase 1	NCT00239746	BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories	UNKNOWN

Publications

12

Molécule	Indication / population	Titre	Journal	Date
Ibuprofen		Discovery of novel ibuprofen-1,3,4-thiadiazole derivatives attenuating ulcerative colitis by regulating MAPK-mediated inflammation and restoring intestinal immune homeostasis.	European journal of medicinal chemistry
Ibuprofen		Targeting CXCL8 in post-traumatic stress disorder and Alzheimer's disease: insights from cross-disorder molecular analysis.	Annals of medicine
Ibuprofen		Statement of Retraction: Ibuprofen promotes p75 neurotrophin receptor expression through modifying promoter methylation and N6-methyladenosine-RNA-methylation in human gastric cancer cells.	Bioengineered
Ibuprofen		Polyphenol-Loaded Liposomal Nanocarriers from : A Promising Nutraceutical Delivery System with Enhanced Bioactivity and Safety.	Molecules (Basel, Switzerland)
Ibuprofen		Acute Pain Management in Children: A Systematic Review and GRADE-Based Recommendations.	Journal of clinical medicine
Ibuprofen		Crosslinked gelatin pastilles prepared via maillard reaction as oral dosage form of ionic liquid pharmaceuticals.	International journal of biological macromolecules
Ibuprofen		Adaptive genetic trade-offs govern the enantioselective degradation and horizontal transfer of ibuprofen catabolic genes.	Journal of hazardous materials
Ibuprofen		Metabolomic insights into migraine: mechanisms and biomarkers from in vivo and clinical studies.	Metabolic brain disease
Ibuprofen		Pulpotomy for an Immature Permanent Tooth With Symptomatic Irreversible Pulpitis Using Cold Ceramic.	Case reports in dentistry
Ibuprofen		Management of moderate pain after orthopaedic surgery: A multiregional expert consensus model for postoperative and discharge protocol development.	Journal of experimental orthopaedics
Ibuprofen		Ketamine-induced cystitis: Lessons from a case of recreational use.	Journal of the American Pharmacists Association : JAPhA
Ibuprofen		Ge-Gen Decoction Modulates the HSP90/AKT Signaling Pathway and the NLRP3 Inflammasome to Alleviate Primary Dysmenorrhea.	Journal of pain research